BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis ...

IPF is a chronic lung disease with fibrous tissue formation, leading to respiratory decline and poor prognosis, affecting mainly older adults. Diagnosis is challenging due to its exclusionary nature, ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

The effect of pollution exposure on IPF severity and progression was not modified by MUC5B promotor polymorphism or telomere length. Long-term exposure to fine particulate matter is associated with a ...

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL ...

There are differences between familial and idiopathic pulmonary fibrosis in terms of cluster of differentiation 20 and CD3 expression.

CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.